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Abstract Ligand-induced activation of receptor tyrosine ki-
nases (RTK) results in the initiation of diverse cellular pathways, 
including proliferation, differentiation and cell migration. The 
ErbB family of RTKs represents a model for signal diversifica-
tion through the formation of homo- and heterodimeric receptor 
complexes. Each dimeric receptor complex will initiate a distinct 
signaling pathway by recruiting a different set of Src homology 
2- (SH2-) containing effector proteins. Further complexity is 
added due to the existence of an oncogenic receptor that 
enhances and stabilizes dimerization but has no ligand (ErbB-
2), and a receptor that can recruit novel SH-2-containing 
proteins, but is itself devoid of kinase activity (ErbB-3). The 
resulting signaling network has important implications for 
embryonic development and malignant transformation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The flow of information from the extracellular environment 
into the cell is at the core of a functional biological system. 
Receptor tyrosine kinases (RTK) are primary mediators of 
many of these signals and thus determine the fate of the 
cell: growth, differentiation, migration or death. RTKs are 
cell-surface allosteric enzymes consisting of a single trans-
membrane domain separating an intracellular kinase domain 
from an extracellular ligand-binding domain. Ligand binding 
induces receptor homo- or heterodimerization that is essential 
for activation of the tyrosine kinase and subsequent recruit-
ment of target proteins, which initiate a complex signaling 
cascade [1,2]. The ErbB family of RTKs consists of four re-
ceptors: ErbB-1, (also called epidermal growth factor receptor 
(EGFR)), ErbB-2 (also called HER2 or Neu), ErbB-3 and 
ErbB-4. Due to extensive receptor-receptor interactions, the 
ErbB family constitutes a signaling network whose potential 
for diversification of biological messages is enormous (Fig. 1). 
Three layers of diversity generation may be distinguished. 
First, two groups of ligands, all sharing an EGF-like motif, 
exist. These are six direct ligands of ErbB-1 and two families 
of neuregulins (also called Neu differentiation factors, NDFs, 
or heregulins). Second, each of the many ligands has a differ-
ent preference for stabilizing distinct receptor dimers, prob-
ably due to ligand bivalency. Third, because each receptor 
dimer has a different double set of tyrosine autophosphoryla-
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tion sites, which serve as docking sites for specific SH2-con-
taining proteins, each ligand-induced receptor dimer funnels 
its signal through a unique set of signaling pathways. Further 
complexity is added to this system by the casting of the fam-
ily: namely, the existence of a receptor that enhances and 
stabilizes dimerization but apparently has no ligand (ErbB-
2) [3] and a receptor that can recruit novel SH2-containing 
proteins, but by itself is devoid of kinase activity (ErbB-3) [4]. 
2. EGF-like ligands and their ErbB receptors 
Six mammalian ligands that bind to ErbB-1 have been char-
acterized, including epidermal growth factor (EGF), trans-
forming growth factor-oc (TGFoc), amphiregulin, heparin-
binding EGF-like growth factor, betacellulin (reviewed in 
[5]), and epiregulin [6]. The binding affinity of the EGF-like 
ligands to ErbB-1 differs as is their potency to induce signal-
ing. In addition, each of the ErbB-1 ligands has a distinct 
expression pattern during development and in adult tissues, 
illustrating the many roles played by ErbB-1. The ligands for 
ErbB-3 and ErbB-4, neuregulins (NRG), are predominantly 
expressed in parenchymal organs and in the embryonic central 
and peripheral nervous systems [7,8]. The different NRG iso-
forms are the products of alternative splicing of a single gene. 
They are synthesized as large transmembrane precursors 
whose extracellular N-terminal domains contain a juxtamem-
brane EGF-like module and various other motifs, depending 
on the isoform. The most important region of the EGF-like 
and NRG ligands is probably the shared EGF-like domain, 
since it is sufficient for binding and receptor activation. This 
region is 45-55 amino acids long and includes six cysteine 
residues which interact covalently to form three loops. 
The extracellular ligand binding domains of the ErbB pro-
teins are relatively conserved among members of the family, 
despite the fact that the receptors bind different ligands. The 
cytoplasmic domains contain the tyrosine kinase catalytic se-
quences and C-terminal autophosphorylation sites which de-
termine the down-stream effector molecules that will be re-
cruited upon phosphorylation. The tyrosine kinase domains 
of ErbB proteins are highly conserved, except for the ErbB-3 
tyrosine kinase domain that shows the least homology. These 
differences include residues that are critically conserved 
throughout the whole family of protein kinases, thus render-
ing ErbB-3 almost devoid of any kinase activity, although it is 
able to bind ATP [9]. 
3. Network function in embryonic development 
Targeted inactivation of components of the ErbB signaling 
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Fig. 1. Schematic representation of the ErbB signaling network. Three layers of diversity generation are proposed: multiple ligands with specif-
icity to distinct receptors, nine receptor combinations, and various sets of cytoplasmic signaling proteins (most of them containing SH2 do-
mains). The plasma membrane is shown as a gray horizontal bar and the various ErbB proteins as bilobular structures with helical transmem-
brane domains. The defective kinase of ErbB-3 is crossed. Receptor phosphorylation sites are shown by encircled P letters. The various 
signaling proteins underlying each receptor dimer are listed in vertical boxes. Receptor heterodimers that can be induced by either EGF (E) or 
NDF/neuregulin (N) are presented with two boxes. Note that only some of the known ErbB ligands are represented and they differ in their 
dimer recruitment abilities. 
network, and expression patterns of ErbB receptors and their 
ligands highlighted the importance of short-range ligand-re-
ceptor interactions especially in mid-gestation inductive proc-
esses. Apparently, the network is involved primarily in two 
types of interactions: mesenchyme-epithel crosstalk and neu-
ronal effects on target cells, including muscle, astroglia, oligo-
dendrocytes and Schwann cells [10]. NRG is synthesized by 
mesenchymal or neuronal cells which influence the differentia-
tion, proliferation and migration of adjacent epithelial or non-
neuronal cells, respectively. An essential role in mid-gestation 
was indicated by embryonic lethality of ErbB-2-, ErbB-4- and 
NRG-deficient mice at around day 10 post-fertilization due to 
aberrant cardiac development [11-14]. Moreover, the non-re-
dundant part played by the NRG receptors and ErbB-2 em-
phasizes that the functional complex is a heterodimer. The 
trabeculae, a finger-like extension of the ventricular myocar-
dium fails to develop, and thus the mutant heart is character-
ized by irregular beat, an enlarged common ventricle and 
reduced blood flow. Since ErbB-4 is expressed in the under-
lying muscular portion of the ventricle and atrium (myocar-
dium) and NRG is expressed in the endothelial ventricular 
lining, it seems that NRG activates trabeculea formation by 
the ErbB-4-expressing myocardium, thereby initiating ventric-
ular differentiation. In addition to cardiac disorders, ErbB-4-
deficient mice displayed severe defects in the development of 
the cranial sensory ganglia following migration from the neu-
ral crest, thus suggesting a unique role for ErbB-4. 
Targeting of the erbB-1 gene demonstrated a pivotal role 
during epithelial cell development, consistent with expression 
profiles of ErbB-1, EGF and TGFa in lung epithelium and in 
the gastrointestinal tract [15-17]. Mutant mice displayed im-
paired epithelial development in several organs, resulting in 
different phenotypes ranging from peri-implantation death to 
live progeny suffering from abnormalities in multiple organs, 
depending on the genetic background. Knockout of one the 
ErbB-1 ligands, namely TGFa, suggested that each ligand 
plays a distinct role during development. Thus, TGFa-dis-
rupted mice displayed only part of the defects observed in 
ErbB-1 null mice, namely eye abnormalities and derangement 
of hair follicles [18,19]. 
An example of a post-birth function of the ErbB network, 
which is obscured by lethality of gene-targeted mice, is pro-
vided by analyses of ErbB receptors in the developing mam-
mary gland. ErbB-1 levels parallel the increase in DNA syn-
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thesis in the mammary gland during pregnancy and decline 
immediately before the onset of lactation [20]. EGF treatment 
of mammary glands, both in vitro and in vivo, resulted in 
ductal and alveolar epithelial differentiation and in the sup-
pression of the accumulation of milk fat droplets in the alveoli 
during mid- to late pregnancy, while overexpression of TGFa 
in mammary glands resulted in earlier alveolar development 
[21-23]. Thus, two different cell populations may function as 
targets of ErbB-1 ligands during distinct stages of mammary 
gland development. In vitro treatment of mammary glands 
with NRG induced formation of lobuloalveolar structures 
and increased appearance of milk-producing cells [24]. The 
NRG isoform a2 is highly expressed during the process of 
lobuloalveolar morphogenesis at pregnancy, and its levels 
markedly decrease during lactation and involution, while no 
expression is detected during the virginal period [25]. Interest-
ingly, a switch between ErbB-3 and ErbB-4 expression was 
observed in the developing mammary gland, suggesting that 
the two receptors play different roles in mammary morpho-
genesis [26]. 
4. ErbB receptors and tumorigenesis 
Overexpression of tyrosine kinase receptors has a deleteri-
ous effect on normal cell growth, leading to the induction of 
transformation [27]. The ErbB-1 receptor provided one of 
the first links between an activated oncogene and human 
tumor biology. Human ErbB-1 is highly homologous to the 
viral oncogene v-erbB, which is carried by an avian retrovirus. 
ErbB-1 is also overexpressed in a variety of human tumors 
and it may undergo oncogenic conversion by gene rearrange-
ments, resulting in large amino-terminal deletions. For 
example, ErbB-1 overexpression is associated with non-small 
cell lung carcinoma and is correlated with high metastat-
ic rate, poor differentiation and short patient survival time 
[28]. 
Amplification and overexpression of erbB-2 have been re-
ported for breast carcinoma, where high levels of erbB-2 were 
correlated with poor prognosis in node-positive patients [29]. 
ErbB-2 is amplified and/or overexpressed in both non-invasive 
and invasive ductal breast carcinoma, reflecting its importance 
in the early as well as progressive stages of tumor develop-
ment. In the rat, a single point mutation in the transmem-
brane domain of ErbB-2 results in a transforming ability, even 
at low expression levels, probably due to constitutive kinase 
activity. Analyses of other types of tumors indicated that 
overexpression of ErbB-2 may be present in most carcinomas, 
including lung adenocarcinomas and gastric and cervical car-
cinomas [30]. 
5. Receptor dimerization and signal diversification 
Similar to other allosteric enzymatic systems, oligomeriza-
tion of ErbB proteins is essential for their activation. Early 
work demonstrated that minimal oligomerization: namely, 
dimer formation, is sufficient for enzyme stimulation [31,32]. 
Furthermore, the extracellular ligand acts as an allosteric reg-
ulator of the cytoplasmic enzyme, simply by inducing recep-
tor/enzyme oligomerization. Thus, the transmembrane topol-
ogy of ErbB proteins allows an allosteric mechanism for 
signal transduction, that bypasses the need for vertical prop-
agation of conformational changes across the plasma mem-
brane. That dimerization is not limited to homodimer forma-
tion, but also includes heterodimerization of ErbB proteins, 
was shown by demonstrating that ErbB-2 can heterodimerize 
with the EGF- [33,34] and NRG-receptors [35]. The driving 
force for homo- as well as heterodimer formation is the higher 
stability of the ternary complex formed between a ligand and 
two receptors, as compared with a monomeric receptor. In 
other words, receptor dimers have higher ligand affinity 
when compared with the corresponding receptor monomers 
[36,37]. It was later demonstrated that at least nine different 
homo- and heterodimers of ErbB proteins exist but their for-
mation displayed a distinct hierarchy [38]. In this network, 
ErbB-2 plays a major coordinatory role, as each liganded 
direct receptor appears to prefer ErbB-2 as its heterodimeric 
partner. This preference is further biased upon overexpression 
of ErbB-2, as seen in many types of human cancer cells. For 
two reasons, ErbB-2-containing heterodimers are character-
ized by extremely high signaling potency. First, due to the 
ability of ErbB-2 to remarkably reduce the rate of ligand 
dissociation, signaling by growth factors is prolonged and 
enhanced by this oncoprotein [39,3]. Second, because ErbB-
2 can efficiently signal through MAP-kinases, its presence en-
hances mitogenic, and perhaps also other types of cellular 
signals [40]. Thus, ErbB-2 overexpression in tumor cells is 
thought to confer a selective advantage due to better utiliza-
tion of stroma-derived EGF-like growth factors. 
Unlike homodimers whose biological activities are relatively 
weak, heterodimers appear to be more potent. This is best 
exemplified by the ability of each ErbB protein to transform 
a normal fibroblast into a cancer cell: co-expression of two 
ErbB proteins, either ErbB-1 and ErbB-2, or each of the two 
NRG receptors together with ErbB-2 or ErbB-1, drives cellu-
lar transformation more efficiently than by each singly ex-
pressed protein [41,42]. In model cellular systems whose 
growth depends on an interleukin, co-expression of two 
ErbB proteins confers a superior proliferative effect, consist-
ent with the synergistic transforming potential [43,4]. A 
graded range of mitogenic signals is thus formed in which 
homodimers of the kinase-defective receptor, ErbB-3, are 
completely inactive and heterodimers between ErbB-3 and 
ErbB-2 are the most mitogenic. The ErbB-2/ErbB-3 hetero-
dimer exemplifies the role of heterodimer formation, not only 
in signal diversification but also in achieving better control; 
formation of the most potent combination requires both a 
ligand for ErbB-3, namely NRG, and a heterodimerizing part-
ner, ErbB-2. 
Does each receptor dimer recruit one unique signaling pro-
tein that allows selection of a distinct signaling pathway? 
Although such a model is attractive when trying to explain 
differential signaling by the various receptor combinations, it 
appears to be incorrect. Like their invertebrate homologs in 
Drosophila and in C. elegans, all ErbB proteins apparently 
utilize the Ras-Raf-MAP-kinase as a major signaling route. 
Nevertheless, each receptor complex may select a distinct set 
of signaling proteins that collectively specify its unique cellu-
lar signature (Fig. 1). Examples include Cbl, a protooncogenic 
adaptor protein, that is recruited by all ErbB-1-containing 
receptor complexes, but not by other dimers [44], and the 
relatively strong association between ErbB-3 and phosphatid-
ylinositol 3'-kinase [45]. Nevertheless, the sets of signaling 
molecules identified so far as recruited to specific receptors 
are largely overlapping. 
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6. Ligand multiplicity and the mechanism of receptor 
dimerization 
Important questions that are currently open include possi-
ble functional redundancy of the multiple ErbB ligands, espe-
cially those sharing receptor specificity. Another question re-
lates to the mechanism by which ligand binding promotes 
dimerization of identical or different receptors. Recent exper-
imental observations imply that the two questions may have a 
common answer. Analysis of N R G signaling indicated that a-
and p-isoforms of this family share an ability to form hetero-
dimers of ErbB-3 with ErbB-2, but only P-isoforms are capa-
ble of stabilizing an ErbB-3/ErbB-l heterodimer [46]. Indirect 
evidence suggest that the many ErbB-1-specific ligands also 
differ in their abilities to recruit different receptor hetero-
dimers [47]. While the mechanism by which each ligand drives 
formation of specific heterodimers may involve a conforma-
tion-induced opening of a cryptic dimerization site, our most 
recent results support a simpler model : namely, N R G mole-
cules appear to contain two receptor binding sites so that 
ligand bivalency may be the sole driving force for dimer for-
mation. Apparently, the two binding sites of N R G differ. 
Whereas the N-terminal site has high affinity and selectively 
binds to both ErbB-4 and ErbB-3, the C-terminally located 
site has low affinity and broad receptor selectivity. Thus, it is 
the interaction with this site that allows selection of the het-
erodimeric receptor partner. Future analyses may identify 
similar broad-specificity sites in other EGF-like ligands, and 
also determine their relative order of receptor selectivity, 
which in the case of N R G s appears to be ErbB-2 > ErbB-3/ 
4 > E r b B - l . 
7. Perspectives 
The ErbB family is able to enhance signal diversification 
through formation of different homo- and heterodimeric in-
teractions. The formation of a specific receptor complex and 
signaling through a selected pathway is most likely governed 
by the available ligands and the receptors expressed by the 
cell. The resulting enormous signal diversity appears needed 
to specify the many cell lineages of the mammalian nervous 
and epithelial systems. Consistent with this possibility, no net-
work is found in lower organisms, but the ErbB family is 
represented in these organisms by a single receptor. It is 
worthwhile to note that most R T K s belong to small families 
of homologous receptors that maintain functional interac-
tions. Therefore, lessons learned in the ErbB family may be 
relevant to the mechanism by which other growth factors and 
their receptors transmit intercellular signals. 
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